首页 Tenax疗法(usTENX)-基本信息

Tenax疗法(usTENX)-基本信息

日报更新时间:

周报更新时间:01-16 11:49

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

中文名称:Tenax疗法


英文名称:Tenax Therapeutics


简介:Tenax Therapeutics, Inc.最初是在一家新泽西公司名下的公司,于1967年成立的,那家新泽西公司叫Rudmer, David & Associates, 随后更名为Synthetic Blood International公司


电话:1-919-8552100


最新量化综合结论
百科信息
  • 相关网站
  • 员工交易记录
  • 持股信息
  • 领导人信息

交易日期 交易人 职位 类型 交易份额 价格
2017-07-30 Jebsen (Michael B) Chief Financial Officer Sell 54 0.65
2017-04-14 Jebsen (Michael B) Chief Financial Officer Sell 56 0.54
2017-03-14 Kelley (John P) Chief Executive Officer Sell 96999 0.68
2017-03-14 Kelley (John P) Chief Executive Officer Buy 213420 --
2016-12-18 Jebsen (Michael B) Chief Financial Officer Sell 49 2.07
2016-11-22 Proehl (Gerald T) Director Buy 14449 1.76
2016-11-21 Proehl (Gerald T) Director Buy 15433 1.59
2016-11-20 Mitchum James P Director Buy 7000 1.51
2016-09-29 Jebsen (Michael B) Chief Financial Officer Sell 49 2.32
2016-08-18 Rallis (Christopher A) Director Buy 10000 2.50
2016-05-31 Jebsen (Michael B) Chief Financial Officer Sell 55 2.72
2016-05-22 Blanck (Ronald Ray) Director Buy 3500 2.62
2016-04-30 Jebsen (Michael B) Chief Financial Officer Buy 430 2.72
2016-02-02 Mitchum James P Director Buy 13900 2.65
2016-02-01 Mitchum James P Director Buy 5100 2.68
2016-02-01 Blanck (Ronald Ray) Director Sell 1800 2.69
2016-01-28 Jebsen (Michael B) Chief Financial Officer Sell 56 2.65
2015-11-18 Blanck (Ronald Ray) Director Buy 1900 3.20
2015-11-18 Blanck (Ronald Ray) Director Buy 4700 3.26
2015-10-30 Jebsen (Michael B) Chief Financial Officer Sell 49 3.19

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
BNY Mellon Investment Management -- -- -33295 -100.00% 2019-03-31
Advisor Group, Inc. 6615 0.11% 6615 -- 2019-03-31
Vanguard Group Inc 12200 0.20% -- -- 2019-03-31
JANE STREET GROUP, LLC 19252 0.31% 19252 -- 2019-03-31
Geode Capital Management, LLC 27658 0.45% -27658 -50.00% 2019-03-31
Fidelity Management & Research Company 33022 0.53% -- -- 2019-07-31
Financial Advisory Service Inc 58576 0.95% -- -- 2019-03-31
Renaissance Technologies Corp 242241 3.91% 77500 47.04% 2019-03-31
BlackRock Inc 599102 9.67% 598475 95450.56% 2019-03-31
UBS Group AG 5817 0.09% -2098 -26.51% 2019-03-31
Northern Trust Investments Inc 3306 0.05% 44 1.35% 2019-07-31
BlackRock Asset Management Canada Ltd 2508 0.04% -2 -0.08% 2019-07-31
Sabby Management LLC -- -- -108427 -100.00% 2019-03-31
Ladenburg Thalmann FI Services Inc 18 -- -- -- 2019-03-31
Morgan Stanley Smith Barney LLC 50 -- -- -- 2019-03-31
Morgan Stanley - Brokerage Accounts 74 -- -1 -1.33% 2019-03-31
USAA Asset Management Company 94 -- -- -- 2019-07-31
Barclays PLC 100 -- -- -- 2019-03-31
BlackRock Advisors (UK) Ltd 100 -- -- -- 2019-03-31
BlackRock Fund Advisors 627 0.01% -- -- 2019-07-31
Mellon Investments Corporation -- -- -4782 -100.00% 2019-03-31
Karp Capital Management Corporation 15 -- 15 -- 2018-12-31
Armistice Capital, LLC 84590 1.37% 84590 -- 2018-12-31
Bank of New York Mellon Corp 38077 0.61% 38077 -- 2018-12-31
Bank of America Corporation 39 -- 33 550.00% 2018-09-30
Dimensional Fund Advisors, Inc. -- -- -14659 -100.00% 2018-12-31
Honkamp Krueger Financial Services Inc 4 -- 4 -- 2018-09-30
Group One Trading, LP 8 -- -- -- 2018-09-30
Deutsche Bank AG -- -- -805 -100.00% 2018-09-30
Prime Capital Investment Advisors, LLC -- -- -100 -100.00% 2018-09-30
Vanguard -- -- -430 -100.00% 2019-01-31
Dimensional Fund Advisors LP 12650 0.42% -- -- 2019-01-31
Wells Fargo & Co -- -- -1 -100.00% 2018-06-30
BNY Mellon Asset Management North America Corporation 401 0.03% 350 686.27% 2018-11-30
UBS Securities LLC 2984 0.20% 1006 50.86% 2018-06-30
Hanson Mcclain Inc 1 -- 1 -- 2018-03-31
Wells Fargo Advisors, LLC 1 -- 1 -- 2018-03-31
Virtu Financial LLC 12576 0.86% 12576 -- 2018-03-31
Merrill Lynch & Co Inc 6 -- 1 20.00% 2018-06-30
Mellon Capital Management Corporation 1646 0.11% 350 27.01% 2018-06-30
Hudock Moyer Wealth Resources, LLC 1 -- 1 -- 2018-03-31
Columbia Management Company 1 -- 1 -- 2018-03-31
Royal Bank Of Canada 1 -- 1 -- 2018-03-31
Vanguard Group Inc. 188 0.01% -- -- 2018-04-30
RA Capital Management, LLC 2389700 8.50% -- -- 2016-12-31
Baker Bros Advisors LP 348374 1.24% 215400 161.99% 2017-09-30
Millennium Management LLC 161600 0.57% -342 -0.21% 2017-09-30
Citadel Advisors Llc 82179 0.29% 41651 102.77% 2017-09-30
Northern Trust Investments N A 51187 0.18% -- -- 2017-09-30
Verition Fund Managegment, LLC 32140 0.12% -- -- 2017-09-30
TWO SIGMA SECURITIES, LLC 21500 0.08% 21500 -- 2017-09-30
Cutter & CO Brokerage, Inc. 15000 0.05% 15000 -- 2017-12-31
Cardinal Capital Management 10000 0.04% -- -- 2017-12-31
Morgan Stanley & Co Inc 2680 0.01% 2470 1176.19% 2017-09-30
BlackRock Advisors LLC 1873 0.01% -- -- 2017-12-31
BlackRock Japan Co Ltd 1100 -- 1100 -- 2016-09-20
WFG Advisors, LP 15000 0.05% -- -- 2017-06-30
KCG AMERICAS LLC 85353 0.30% 85353 -- 2017-06-30
Tower Research Capital LLC 13046 0.05% 13046 -- 2017-06-30
Broadfin Capital, LLC 1968631 7.00% -- -- 2016-09-30
Great Point Partners LLC 1108593 3.94% -- -- 2016-09-30
Opaleye Management Inc 390000 1.39% -75000 -16.13% 2016-09-30
EverPoint Asset Management, LLC 345000 1.23% 195000 130.00% 2016-09-30
Commerzbank AG 200000 0.71% -100000 -33.33% 2016-09-30
Bourgeon Capital Management LLC 94000 0.33% 28500 43.51% 2016-09-30
Oppenheim Asset Mgmt Services S.¨¤ r.l. 92900 0.33% -- -- 2016-09-30
Apo Asset Management GmbH 103966 0.37% -- -- 2016-12-31
Medical Strategy GmbH 96200 0.35% -- -- 2016-12-31
Nationwide Fund Advisors 70000 0.25% 10000 16.67% 2016-09-30
John P. Kelley 1613121 8.00% 5952416 0.10% 1999-11-30
Doug Randall 1613121 8.00% 5952416 0.10% 1999-11-30
Sabby Healthcare Master Fund, Ltd. 2354567 8.00% 8688352 0.10% 1999-11-30
Gregory Pepin 2364956 8.00% 8726688 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
DFA US Small Cap Portfolio -- -- -6712 -100.00% 2018-12-31
Vanguard Extended Market Index Fund 12200 0.20% -- -- 2019-06-30
NT Ext Equity Market Index Fund - L 1240 0.02% -- -- 2019-06-30
NT Extended Equity Market Idx Fund - NL 1057 0.02% -- -- 2019-06-30
NT Ext Equity Mkt Fd - DC - NL 756 0.01% 55 7.85% 2019-06-30
iShares Core S&P Total US Stock Mkt ETF 627 0.01% -- -- 2019-07-30
iShares Core MSCI AllCntry Wld exCan ETF 627 0.01% -- -- 2019-05-30
iShares Core Growth ETF Portfolio 627 0.01% -- -- 2019-05-30
iShares Core Balanced ETF Portfolio 627 0.01% -- -- 2019-05-30
iShares Core S&P US Total Market ETF 627 0.01% -- -- 2019-05-30
NT US Market Cap Index Fund - Lending 253 -- -- -- 2019-06-30
USAA Extended Market Index Fund 94 -- -- -- 2019-06-30
Fidelity 51 -- -- -- 2019-06-30
iShares Core S&P US Total Mkt ETF CADH -- -- -2 -100.00% 2019-05-09
DFA US Targeted Value Portfolio -- -- -5938 -100.00% 2018-12-31
BNYM Mellon SL Mkt Completion Fd -- -- -371 -100.00% 2019-06-30
BNYM Mellon NSL Mkt Completion Fd Instl -- -- -1265 -100.00% 2019-06-30
Vanguard US Equity Index Fund -- -- -188 -100.00% 2018-12-31
NT Ext Equity Mkt Idx Fd - DC - NL 756 0.01% 55 7.85% 2019-06-30
NT US Market Cap Index Fund - NL -- -- -11 -100.00% 2018-12-31
BNYM Mellon NSL Market Completion Fund 1265 0.02% 1215 2430.00% 2019-03-31
BNYM Mellon SL Market Completion Fund 371 0.01% -894 -70.67% 2019-03-31
The Vanguard Total Stock Market Index -- -- -430 -100.00% 2018-06-30
BNY Mellon Market Completion Fund 50 -- -351 -87.53% 2018-12-31
Master Extended Market Index Series -- -- -94 -100.00% 2018-02-28
Vanguard Balanced Index Fund 12702 0.87% -18298 -59.03% 2017-09-30
Vanguard Total Stock Market Index Fund 647032 44.15% -- -- 2017-07-31
Vanguard Extended Market Idx Inv 12200 0.84% -- -- 2018-07-31
DFA US Small Cap I 6712 0.46% -- -- 2018-07-31
BNY Mellon EB DL Mkt Completion 1245 0.09% -- -- 2018-06-30
DFA US Targeted Value I 5938 0.41% -- -- 2018-07-31
iShares Core S&P Total US Stock Mkt 627 0.05% -- -- 2018-09-12
BNY Mellon Market Completion Fund UC1 401 0.03% 350 686.27% 2018-03-31
USAA Extended Market Index 94 0.01% -- -- 2018-07-31
Fidelity Spartan 69 -- -- -- 2018-07-31
Vanguard Total Stock Mkt Idx 670313 2.38% -91455 -12.01% 2016-12-31
Nationwide Bailard Tech&Sci M 70000 0.25% -- -- 2016-12-31
Vanguard Balanced Index Inv 31000 0.11% -- -- 2016-12-31
iShares Micro-Cap 56114 0.30% -- -- 2017-02-07
AXA/Lord Abbett Micro Cap K 4318 0.02% -- -- 2016-11-30
AZL 2907 0.01% -- -- 2016-12-31
Fidelity Spartan® Extended Mkt Indx Fd 74064 0.30% -- -- 2015-09-30
APO Medical Opportunities 50100 0.20% -- -- 2015-10-31
Finen Inversiones SICAV 39045 0.10% -50 -0.10% 2015-06-30
Mellon Capital EB DL Mkt Completion Fund 31609 0.10% -- -- 2015-09-30
Nationwide Bailard Tech&Sci Fund 25000 0.10% -- -- 2015-10-31
apo Medical Opportunities Institutionell 15000 -- -- -- 2015-10-31
PHARMA/wHEALTH 11700 -- -- -- 2015-09-30
RIM Global CC Bioscience 5886 -- -- -- 2015-09-30
AZL® DFA US Small Cap Fund 5663 -- -- -- 2015-09-30
Fidelity® NASDAQ Composite Index® Fund 4974 -- -- -- 2015-09-30
FCP OP MEDICAL BioHealthTrends 81200 0.30% -- -- 2015-09-30

Ronald R. Blanck Ronald R. Blanck is a businessperson who has been at the head of 6 different companies. Presently, he is Chairman of VetFed Resources, Inc., Chairman of Martin, Blanck & Associates, Chairman of Tenax Therapeutics, Inc. and Chairman at Pyng Medical Corp. Ronald R. Blanck is also on the board of Ology Bioservices, Inc. and Chairman at Educational Commission for Foreign Medical Graduates, Inc. and Chairman-Regents Board at Uniformed Services University of the Health Sciences. In the past he was Chief-Department of Medicine at Brooke Army Medical Center, Principal at The United States Army (District of Columbia) and President of the University of North Texas Health Science Center. He received an undergraduate degree from Philadelphia College of Osteopathic Medicine.
Gerald T. Proehl Gerald T. Proehl founded Salix Pharmaceuticals Ltd., Santarus, Inc. and Dermata Therapeutics LLC. Presently, Mr. Proehl is President, Chief Executive Officer & Director at Dermata Therapeutics LLC and President of Covella Pharmaceuticals, Inc. Mr. Proehl is also on the board of 6 other companies. He previously held the position of President, Chief Executive Officer & Director at Santarus, Inc., Executive Vice President-Global Marketing at Hoechst Marion Roussel, Inc. and Vice President-Global Marketing at HMR Pharma, Inc. Gerald T. Proehl received a graduate degree from Wake Forest University, an MBA from Rockhurst University and an undergraduate degree from State University of New York College at Cortland.
Chris A. Rallis Chris A. Rallis is on the board of Tenax Therapeutics, Inc., Fennec Pharmaceuticals, Inc., Aeolus Pharmaceuticals, Inc. and Salisbury School, Inc. In his past career Mr. Rallis was President & Chief Executive Officer at ImmunoBiosciences, Inc., President, Chief Operating Officer & Director at Triangle Pharmaceuticals, Inc. and VP-Strategic Planning & Business Development at Burroughs Wellcome. He received a graduate degree from Duke University and an undergraduate degree from Harvard College.
Anthony A. DiTonno Anthony A. DiTonno holds the position of Chairman of Avantis Medical Systems, Inc. and Chief Executive Officer & Director at Tenax Therapeutics, Inc. In his past career Mr. DiTonno held the position of President, Chief Executive Officer & Director at NeurogesX, Inc., President & Chief Executive Officer at LifeSleep Systems, Inc., Principal at Rorer Group, Inc., Principal at Wyeth Laboratories, Inc., Executive Vice President-Sales & Marketing at Enteric Medical Technologies, Inc. and Vice President & General Manager at Oclassen Pharmaceuticals, Inc. Mr. DiTonno received an MBA from Drexel University and an undergraduate degree from St. Joseph's University.
James P. Mitchum James P. Mitchum is a businessperson who has been at the head of 6 different companies and is Chief Executive Officer at Regalorx. He is also on the board of Tenax Therapeutics, Inc. and Medpace Research, Inc. In the past Mr. Mitchum held the position of Chief Executive Officer for Aventis Pharma UK, President & Chief Executive Officer for Sanofi-Aventis Japan, President & Chief Operating Officer for Medi-Flex Ltd., President & Chief Executive Officer of Enturia, Inc., President-Americas Region at EUSA Pharma, Inc., Controller for HMR Pharma, Inc., Controller of Hoechst Marion Roussel, Inc. and Chief Executive Officer & Director at Heart to Heart International, Inc. He received an MBA from the University of Tennessee and an undergraduate degree from Milligan College.
Michael B. Jebsen Michael B. Jebsen occupies the position of President, CFO & Principal Accounting Officer at Tenax Therapeutics, Inc. In his past career Mr. Jebsen occupied the position of Auditor of Grant Thornton LLP, Auditor at Grant Thornton LLP and Chief Ethics Officer & Senior Internal Auditor at Research Triangle Institute. He received a graduate degree from East Carolina University.
Gregory Pepin Gregory Pepin founded Vatea Fund, EOS Investment Ltd. and Independent Wealth Management SA. Currently, he occupies the position of Managing Director at Vatea Fund and Chief Executive Officer for Danish Silver A. Mr. Pepin is also on the board of Tenax Therapeutics, Inc. and Theravectys SAS and Fund Manager at Hades Investment Ltd. and Executive Manager at Deltec Bank & Trust Ltd. Gregory Pepin previously occupied the position of Senior Vice President of Melixia SA, Managing Director at Cedrus Capital LLP and Managing Director at FGP Capital France. Mr. Pepin received an undergraduate degree from the University of Lausanne.
Nancy J. Hecox Presently, Nancy J. Hecox holds the position of Secretary, EVP-Legal Affairs & General Counsel at Tenax Therapeutics, Inc. She is also Member of The North Carolina State Bar. She received an MBA from East Carolina University, an undergraduate degree from The State University of New York and a graduate degree from North Carolina Central University.
Doug Randall Founder of Phyxius Pharma, Inc., Doug Randall presently is Executive VP-Commercial & Business Operations at Tenax Therapeutics, Inc. In the past he was Vice President-Commercial Operations at The Medicines Co., Chief Commercial Officer at Phyxius Pharma, Inc., Vice President-US Diabetes Marketing at Sanofi-Aventis Pharmaceuticals and Vice President-Sales at Aventis Pharmaceuticals, Inc. Doug Randall received an undergraduate degree from the University of Rhode Island.
Douglas Hay Douglas Hay founded Phyxius Pharma, Inc. He is Executive Vice President-Regulatory Affairs at Tenax Therapeutics, Inc. He previously occupied the position of Vice President-Global Regulatory Sciences at Bristol-Myers Squibb Co. and Vice President-Regulatory Affairs at Phyxius Pharma, Inc. Dr. Hay received an undergraduate degree from the University of California, Riverside, a graduate degree from The California State University and a doctorate from Northern Arizona University.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐